Cardinal Health Slides 0.69% With 238th Volume Rank as Analysts Boost Price Targets to $245

Market Snapshot

On March 23, 2026, shares of Cardinal Health (CAH) fell 0.69%, closing at $207.91. The stock saw a trading volume of $0.53 billion, a 39.6% decline from the previous day, ranking it 238th in volume among all traded stocks. The 50-day moving average stands at $217.62, while the 200-day average is $194.73, indicating the current price is near the midpoint of its 52-week range ($120.72 to $233.60). The company’s market capitalization remains at $48.9 billion, with a P/E ratio of 29.92 and a beta of 0.65, reflecting defensive positioning relative to broader markets.

Key Drivers

Analyst sentiment for Cardinal Health has remained overwhelmingly positive, with a “Moderate Buy” consensus rating from 17 firms. Fourteen analysts have assigned a “Buy” rating, two a “Hold,” and one a “Strong Buy.” Recent upgrades from Barclays, Evercore, and TD Cowen have raised price targets to $258, $260, and $251, respectively, pushing the average 12-month price objective to $245.67. This optimism is underpinned by the company’s recent earnings performance, which saw a $2.63 per share profit in the first quarter—$0.32 above estimates—and $65.63 billion in revenue, a 18.8% year-over-year increase. Despite a negative return on equity of 92.50%, the earnings beat and revenue growth suggest operational resilience in its healthcare supply chain and distribution services.

Institutional investor activity further reinforces confidence in the stock. Procyon Advisors LLC increased its stake by 78.7% in Q4, holding $3.5 million worth of shares, while other firms, including SJS Investment Consulting and Jones Financial Companies, also boosted holdings by over 100%. These moves highlight growing institutional conviction in Cardinal Health’s long-term value proposition, particularly in its role as a critical infrastructure provider for hospitals, pharmacies, and clinical labs. Hedge funds and institutional investors collectively own 87.17% of the stock, signaling deep alignment with analyst expectations.

The company’s recent dividend announcement also contributes to its appeal. A $0.5107 quarterly payout, annualized at $2.04, yields 1.0% and maintains a payout ratio of 29.35%, balancing shareholder returns with reinvestment capacity. While the yield is modest compared to sector peers, the stability of the dividend—amid rising acute care demand and a 18.8% revenue growth—positions Cardinal Health as a defensive play in a volatile market.

However, the stock’s 0.69% decline on March 23 suggests short-term caution, potentially linked to broader market jitters or sector-specific concerns. The drop in trading volume by nearly 40% may reflect reduced speculative activity or profit-taking following recent analyst upgrades. Despite this, the stock remains well above its 200-day moving average and within a $30 range of its 52-week high, indicating strong underlying fundamentals. Analysts and institutional investors appear focused on long-term growth, with Cardinal Health’s market position in healthcare logistics and its ability to navigate inflationary pressures and supply chain disruptions serving as key tailwinds.

Conclusion

While short-term volatility persists, the confluence of analyst upgrades, robust earnings, and institutional buying underscores Cardinal Health’s strategic value in the healthcare sector. With a clear path to outperforming its 12-month price target of $245.67 and a resilient business model, the stock remains a focal point for investors seeking exposure to the healthcare distribution value chain.